Fiche centre
Research Site
Centennial — United States
Essais liés3clinical trials
VilleCentenniallocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT03222973
Essais cliniques associés
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| BIIB033 (opicinumab) | SEP | Phase 2 | NCT03222973 | AFFINITY — Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) | TERMINATED |
| natalizumab | SEP | Phase 1 | NCT00559702 | Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) | COMPLETED |
| BIIB033 | SEP | Phase 1 | NCT01244139 | Safety Study of BIIB033 in Subjects With Multiple Sclerosis | COMPLETED |